Isaac Neuhaus

Guest Editor for the following articles:

Jun
2012
Vol. 31. No. 2

Fillers: From the Past to the Future

Richard G. Glogau, MD

Modern medical use of injectable soft-tissue augmentation fillers has evolved from the
introduction of bovine collage implants to an array of synthesized materials in the current
domestic and foreign markets. The concept of augmentation has moved from simple lines,
scars, and wrinkles to revolumizing the aging face. A brief overview of the past, present,
and future injectable fillers is presented.
Semin Cutan Med Surg 31:78-87 © 2012 Elsevier Inc. All rights reserved.

MORE
Jun
2012
Vol. 31. No. 2

New Frontiers in Laser Surgery

Doru T. Alexandrescu, MD

The simultaneous advances in engineering, medicine, and molecular biology have accelerated
the pace of introductions of new light-based technologies in dermatology. In this
review, the authors examine recent advances in laser surgery as well as peer into the future
of energy-based cutaneous medicine. The future landscape of dermatology will almost
undoubtedly include (1) noninvasive imaging technologies and (2) improved “destructive”
modalities based on real-time feedback from the skin surface.
Semin Cutan Med Surg 31:88-97 © 2012 Elsevier Inc. All rights reserved.

MORE
Mar
2007
Vol. 26. No. 1

Complications of Sclerotherapy

Girish S. Munavalli, MD, Mhs | Robert A Weiss, MD, FAAD, FACPh

Sclerotherapy is the systematic, targeted elimination of intracutaneous and subcutaneous varicose, reticular, telangiectasias by the injection of a locally irritating chemical substance, called a sclerosant. The endpoint of this process is functionally analogous to surgical removal of a vein.

MORE
Jun
2012
Vol. 31. No. 2

The Horizon for Treating Cutaneous Vascular Lesions

Amit M. Patel, MD | Elizabeth L. Chou, BS | Kristen M. Kelly, MD

Dermatologists encounter a wide range of cutaneous vascular lesions, including infantile
hemangiomas, port-wine stain birthmarks, arteriovenous malformations, venous malformations,
Kaposi sarcomas, angiosarcomas, and angiofibromas. Current treatment modalities to
reduce these lesions include topical and/or intralesional steroids, laser therapy, surgical
resection, and endovascular therapy. However, each method has limitations owing to recurrence,
comorbidities, toxicity, or lesion location. Photodynamic therapy, antiangiogenic therapy,
and evolving methods of sclerotherapy are promising areas of development that may mitigate
limitations of current treatments and offer exciting options for patients and their physicians.
Semin Cutan Med Surg 31:98-104 © 2012 Elsevier Inc. All rights reserved.

MORE